- Tytuł:
- 122P Casdozokitug (casdozo, SRF388), a first-in-class IL-27 targeting antibody, as monotherapy (monotx) or in combination with pembrolizumab (pembro) in treatment-refractory non-small cell lung cancer (NSCLC)
- Autorzy:
- Źródło:
- In Immuno-Oncology and Technology December 2023 20 Supplement
Czasopismo naukowe